Cicloral versus neoral: A bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of Cicloral

被引:13
作者
Kees, F
Mair, G
Dittmar, M
Bucher, M
机构
[1] Univ Regensburg, Dept Pharmacol, D-93053 Regensburg, Germany
[2] Univ Regensburg, Dept Anesthesiol, Regensburg, Germany
关键词
D O I
10.1016/j.transproceed.2004.10.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The bioavailability of cyclosporine a (CyA) was assessed in 2 cross-over studies with 12 healthy male volunteers each. Study A compared the bioavailability of Cicloral (test) with the microemulsion Neoral (reference) in the fasting state. Study B examined the influence of a fat-rich meal composed according to the Food and Drug Administration (FDA) recommendations on the bioavailability of Cicloral. Each volunteer received a single dose of 200 mg CyA in each period. Whole blood CyA concentrations were determined using HPLC up to 48 hours after drug administration. The pharmacokinetic parameters were determined using standard noncompartmental methods. The mean bioavailability of Cicloral compared with Neoral amounted to 83% (AUC) and 78% (Cmax), respectively. When administered after a fat-rich meal, the bioavailability of Cicloral was 121% (AUC) and 132% (Cmax) compared with fasting administration. Time to Cmax was 1.3 to 1.4 hours for both medications and modes of administration. Bioequivalence could not be proven either between Cicloral and Neoral, or between Cicloral fasting versus after a fat-rich meal. We conclude that the lower bioavailability and the influence of food on the bioavailability of Cicloral must be taken into account when switching from Neoral to the generic formulation.
引用
收藏
页码:3234 / 3238
页数:5
相关论文
共 20 条
[1]   High-performance liquid chromatographic method for therapeutic drug monitoring of cyclosporine A and its two metabolites in renal transplant patients [J].
Brozmanová, H ;
Grundmann, M ;
Safarcik, K ;
Jegorov, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2000, 749 (01) :93-100
[2]   ALTERNATIVE CYCLOSPORINE METABOLIC PATHWAYS AND TOXICITY [J].
CHRISTIANS, U ;
SEWING, KF .
CLINICAL BIOCHEMISTRY, 1995, 28 (06) :547-559
[3]   Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations [J].
Durlik, M ;
Rauch, C ;
Thyroff-Friesinger, U ;
Streu, H ;
Paczek, L .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (04) :1304-1307
[4]   CYCLOSPORINE CLINICAL PHARMACOKINETICS [J].
FAHR, A .
CLINICAL PHARMACOKINETICS, 1993, 24 (06) :472-495
[5]  
FDA, 2002, GUID IND FOOD EFF BI
[6]  
First MR, 1998, CLIN TRANSPLANT, V12, P518
[7]   Drug, meal and formulation interactions influencing drug absorption after oral administration - Clinical implications [J].
Fleisher, D ;
Li, C ;
Zhou, Y ;
Pao, LH ;
Karim, A .
CLINICAL PHARMACOKINETICS, 1999, 36 (03) :233-254
[8]   EFFECT OF FOOD ON THE PHARMACOKINETICS OF CYCLOSPORINE IN HEALTHY-SUBJECTS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION [J].
GUPTA, SK ;
MANFRO, RC ;
TOMLANOVICH, SJ ;
GAMBERTOGLIO, JG ;
GAROVOY, MR ;
BENET, LZ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (07) :643-653
[9]   Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: Does fat intake still matter? [J].
Klauser, RM ;
Irschik, H ;
Kletzmayr, J ;
Sturm, I ;
Brunner, W ;
Woloszczuk, W ;
Kovarik, J .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (07) :3137-3140
[10]   Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine A in rats [J].
Koehler, J ;
Kuehnel, T ;
Kees, F ;
Hoecherl, K ;
Grobecker, HF .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (06) :658-662